Skip to main content

Table 3 Characteristics of patients who were or were not referred to cardiology

From: Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

 

Cardiology referral (n = 75)

No referral (n = 39)

P value

Year of diagnosis

  

0.076

 2010

11 (15%)

9 (23%)

 

 2011

24 (32%)

15 (38%)

 

 2012

24 (32%)

11 (28%)

 

 2013

16 (21%)

4 (10%)

 

Location

  

0.041

 4o care centre

20 (26%)

4 (10%)

 

 Peripheral centre

55 (73%)

35 (90%)

 

Age at diagnosis (y)

57 ± 10

56 ± 12

0.714

T

  

0.877

 0

1 (1%)

0

 

 1

27 (37%)

14 (36%)

 

 2

33 (45%)

20 (51%)

 

 3

3 (4%)

2 (5%)

 

 4

10 (14%)

3 (8%)

 

N

  

0.143

 0

40 (54%)

13 (34%)

 

 1

24 (32%)

19 (50%)

 

 2

6 (8%)

2 (5%)

 

 3

4 (5%)

4 (11%)

 

Mastectomy

58 (77%)

38 (97%)

0.005

Radiation

58 (77%)

29 (74%)

0.723

Radiation dose (Gy)

55 (42.5,90)

80 (0,92.5)

0.667

Anthracycline dose (mg/m2)

240 (150,240)

240 (150,240)

0.298

Pre-existing CVD

4 (5%)

2 (5%)

0.963

CV risk factors

39 (52%)

18 (46%)

0.554

Baseline LVEF

61% ±6

60% ±7

0.435

LVEF at time of deterioration

45% (42,47)

47% (45,48)

0.003

Symptoms of HF

24 (32%)

3 (8%)

0.004

  1. Values shown are counts (percentages), mean ± SD, or median (Q1, Q3). Abbreviations: CV Cardiovascular, CVD Cardiovascular disease, HF Heart failure, LVEF Left ventricular ejection fraction, N Nodal stage, T Tumour stage